Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

AstraZeneca wins big (again ... from a more effective frontline therapy than if you wait till a second one." Pfizer impresses in colorectal cancer – The company's pill Braftovi, combined ...

Here are some data highlights and executive commentary from the larger companies I follow: AstraZeneca wins big ... if you wait till a second one." Pfizer impresses in colorectal cancer ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection ... for RSV prevention reach the market. Pfizer is currently leading the race ...

What are the best stocks right now for investors in the cancer drug development space? Seeking Alpha analysts offer their ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...